尿路感染症に対するS-6436の基礎的,臨床的研究
スポンサーリンク
概要
- 論文の詳細を見る
S-6436, a new long-acting preparation of cephalexin (CEX), was studied both basically and clinically in the urological field and the results obtained were as follows:<BR>1. In vitro antibacterial activity<BR>MICs of CEX against clinically isolated 73 strains of E. coli were distriblited among ≤0.2≥100μg/ml with inoculum size of 10<SUP>8</SUP> cells/ml but the majority of MICs was ≥100μg/ml. On the other hand, with inoculum size of 10<SUP>6</SUP> cells/ml a peak of MIC distribution was 3.12μg/ml.<BR>MICs of CEX against clinically isolated 15 strains of Klebsiella pneumoniae were distributed among 50-≥100μg/ml mostly ≥100μg/ml, with inoculum size of 10<SUP>8</SUP> cells/ml but with 10<SUP>6</SUP> cells/ml a peak was 3.12μg/ml.<BR>MICs of CEX against clinically isolated 95 strains of Serratia marcescens and 18 strains of Pseudomonasaeruginosa were mostly ≥100μg/ml with both inoculum sizes of 108 and 106 cells/ml.<BR>2. Serum level<BR>Three healthy adult volunteers were orally administered S-6436 at a single dose of 500mg after usual meal. Mean peak serum concentration of S-6436 was appeared at five hours with 6.8μg/ml and effective serum levels continued for approximately five hours. Accordingly it is considered that therapeutic efficacy of S-6436 can be expected at a dose of 500mg b.i.d.<BR>3. Urinary recovery<BR>The urinary recovery of S-6436 for twelve hours was 83.1% on an average following an administration of a single dose of 500mg.<BR>4. Clinical result<BR>S-6436 was administered to the majority of 20 cases with urinary tract infections at a dose of 500mg b.i.d., and the clinical effects obtained were excellent in 15 cases, good in 3 cases and poor in 2 cases, effective ratio being 90%. In 13 cases with simple urinary tract infections, the effective ratio was 92% and in 7 cases with complicated urinary tract infections, the effective ratio was 86%.<BR>5. Adverse reaction<BR>In S-6436 administered 20 cases, no adverse reactions were complained. These results indicated that S-6436 was equal to CEX in the effectiveness and safety in the therapy of urinary tract infection. Accordingly it is considered that S-6436 500mg b.i.d. is more acceptable and more convenient for patients than CEX 250mg q.i.d.
- 日本感染症学会の論文
日本感染症学会 | 論文
- 看護学生における風疹, 麻疹, 水痘, ムンプス感染防止対策 : 抗体価測定とワクチン接種
- 本邦において初めて流行が確認された小児の human metapneumovirus 感染症の臨床的, 疫学的解析
- つつが虫病および日本紅斑熱について発生頻度が異なる地域での市民医学講座参加者における認知度比較
- 日本の検疫所における遠隔疫学調査による多剤耐性赤痢菌株のインド国内における定着の証明
- HIV-1感染者血清中の逆転写酵素活性阻止抗体の動態